Add BrightSurf on Google Email

Researchers at the GIST identify new medicines using interpretable deep learning predictions

A new deep learning-based model called Highlights on Target Sequences (HoTS) predicts binding between drugs and target molecules, providing interpretable results. The model can predict target proteins' binding regions and interactions with drugs without a 3D complex.

SourceGIST (Gwangju Institute of Science and Technology)·JournalJournal of Cheminformatics·TypeComputational simulation/modeling·DateApr 5, 2022

Plant compound shows promise for alleviating food allergies

Researchers have identified formononetin as a potential therapeutic for treating food allergies, which affect nearly 10% of the world population. The plant compound has been shown to decrease IgE production and influence gene and protein targets regulated in food allergy and mast cell diseases.

SourceExperimental Biology·DateApr 1, 2022

NCCN pharmacy directors forum publishes recommendations for safely dispensing investigational medications for clinical trials

The National Comprehensive Cancer Network has published new consensus recommendations to improve the safety and efficiency of research studies involving investigational drugs. The recommendations focus on seven areas, including pharmacy workflows and collaboration with sponsors.

SourceNational Comprehensive Cancer Network·JournalAmerican Journal of Health-System Pharmacy·DateMar 15, 2022

"Hotspot mapping" accelerates early-phase drug design

Researchers from CCDC, Exscientia, and Oxford University have developed an automated method for informing the design of compound selectivity across protein families. The 'Hotspot API' uses ensemble hotspot maps to quantify the propensity for compounds to exploit interactions in preferred binding sites.

SourceCCDC - Cambridge Crystallographic Data Centre·JournalJournal of Chemical Information and Modeling·DateMar 2, 2022
Apple iPad Pro 11-inch (M4)

Apple iPad Pro 11-inch (M4) runs demanding GIS, imaging, and annotation workflows on the go for surveys, briefings, and lab notebooks.

Data from Codiak’s exoASO™-STAT6 preclinical development program for the treatment of primary and metastatic hepatic cancers published in Science Advances

Codiak BioSciences' exoASO-STAT6 demonstrates potent anti-tumor efficacy by reprogramming tumor-associated macrophages to an M1 phenotype, showing promise as a monotherapy candidate for hepatocellular carcinomas and other cancers. The company plans to initiate Phase 1 clinical trials in the first half of 2022.

SourceScient Public Relations, Inc.·JournalScience Advances·TypeExperimental study·DateFeb 18, 2022

Review highlights potential of structural proteomics for treating neurodegenerative diseases

A recent review highlights the potential of structural proteomics in understanding pathological processes and predicting drug candidates for neurodegenerative diseases. The field combines protein chemistry and mass spectrometry to determine protein structure and interactions, which can lead to breakthroughs in treating serious health c...

SourceSkolkovo Institute of Science and Technology (Skoltech)·JournalChemical Reviews·DateJan 27, 2022

Researchers of the University of Kent and Goethe-University Frankfurt find explanation why the Omicron variant causes less severe disease

A new study reveals that the Omicron variant is sensitive to inhibition by the interferon response, an unspecific immune reaction present in all body cells. This provides the first explanation for why COVID-19 patients infected with Omicron are less likely to experience severe disease.

SourceGoethe University Frankfurt·JournalCell Research·TypeExperimental study·DateJan 24, 2022
SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.

NIH researchers identify potential AMD drugs with stem-cell based research tool

Researchers developed a dish-based model that replicates the characteristics of dry age-related macular degeneration, allowing them to screen over 1,200 drugs for their ability to slow or halt disease progression. Two drugs, Aminocaproic acid and L745, showed promise in inhibiting key phenotypes associated with AMD.

SourceNIH/National Eye Institute·JournalNature Communications·TypeExperimental study·DateDec 15, 2021

Now scientists can efficiently screen billions of chemical compounds to find effective new drug therapies

Researchers at USC Dornsife College of Letters, Arts and Sciences have created a process that increases the chances of finding effective drugs in a fraction of the time and at significantly less expense than current methods. V-SYNTHES, a virtual method developed by Vsevolod Katritch and colleagues, uses synthons to efficiently puzzle t...

SourceUniversity of Southern California·JournalNature·TypeComputational simulation/modeling·DateDec 15, 2021

Are scientists homing in on a cure for Parkinson’s disease?

Researchers at the University of Bath have optimised a peptide that prevents alpha-synuclein misfolding, a key feature of Parkinson's disease. The new molecule, 4654W(N6A), has shown significant promise in lab experiments and could lead to the development of a disease-modifying treatment.

SourceUniversity of Bath·JournalJournal of Molecular Biology·TypeExperimental study·DateDec 9, 2021
Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

Taking new aim at COVID-19

Researchers at Duke University have identified chemical compounds that can latch onto the coronavirus's 3D RNA structures and block replication. The compounds, which target the virus's RNA specifically, offer a new mechanism of action against COVID-19.

SourceDuke University·JournalScience Advances·TypeExperimental study·DateNov 26, 2021
Apple MacBook Pro 14-inch (M4 Pro)

Apple MacBook Pro 14-inch (M4 Pro) powers local ML workloads, large datasets, and multi-display analysis for field and lab teams.

Biased beta-agonists may provide better control of asthma and other obstructive lung diseases, drug discovery study shows

A University of South Florida Health-led team discovered a lead candidate that selectively relaxes airway smooth muscle cells with no detectable drug desensitization. The biased beta-agonist, C1-S, offers a therapeutic option for asthma and obstructive lung diseases without the rapid loss of effectiveness seen with traditional β-agonists.

SourceUniversity of South Florida (USF Health)·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateNov 22, 2021

Rice web server helps identify COVID-19 drug candidates

Researchers developed a new online portal, DINC-COVID, to speed up the identification of potential pandemic treatments. The platform incorporates models of three drug targets and uses ensemble docking to score ligands' success in binding.

SourceRice University·JournalComputers in Biology and Medicine·TypeComputational simulation/modeling·DateNov 1, 2021
Sky & Telescope Pocket Sky Atlas, 2nd Edition

Sky & Telescope Pocket Sky Atlas, 2nd Edition is a durable star atlas for planning sessions, identifying targets, and teaching celestial navigation.

Picomolar antimalarial agent from a Chinese medicinal plant

Researchers at Shanghai Institute of Materia Medica have isolated and characterized seven novel dimeric sesquiterpenoids with potent antimalarial activities. The most potent compound, Shizukaol A, exhibits an EC50 value 1000-fold more active than artemisinin.

SourceScience China Press·JournalScience China Chemistry·DateOct 27, 2021

Early-stage drug candidate diminishes deficits in Parkinson's disease

Researchers have identified a molecule that slows cells' production of alpha-synuclein, a protein forming toxic aggregates in Parkinson's brains. The compound, A-443654, also reduces cell stress and may help degrade existing alpha-synuclein aggregates.

SourceUniversity of Utah Health·JournalJournal of Biological Chemistry·TypeExperimental study·DateSep 22, 2021
Meta Quest 3 512GB

Meta Quest 3 512GB enables immersive mission planning, terrain rehearsal, and interactive STEM demos with high-resolution mixed-reality experiences.

Molecular mechanisms of corona drug candidate Molnupiravir unraveled

Researchers at Max Planck Institute elucidated the molecular mechanism of Molnupiravir, an antiviral agent that reduces Sars-CoV-2 coronavirus transmission. By incorporating RNA-like building blocks into the virus genome, Molnupiravir prevents further replication and transmission.

SourceMax-Planck-Gesellschaft·JournalNature Structural & Molecular Biology·DateAug 16, 2021

Heart cell protein could lead to new treatments for heart failure and recovery

Researchers discovered that a protein called VDAC2 plays a key role in regulating calcium signaling within heart cells, which can help prevent chronic heart failure. Targeting this protein with drugs or therapeutic treatments may eventually alleviate heart failure.

SourceUniversity of Utah Health·JournalNature Communications·TypeRandomized controlled/clinical trial·DateJul 28, 2021
DJI Air 3 (RC-N2)

DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.

UIC awarded $6 million to develop potential COVID-19 treatment

Researchers at UIC are developing a potential COVID-19 treatment using VT-109, which has shown promise in animal models by restoring lung function and reducing inflammation. The new funding will be used to conduct pre-clinical studies to determine efficacy, toxicity, and dosages before human trials.

SourceUniversity of Illinois Chicago·DateJul 28, 2021

Repairing hearts with deadly spider venom

A drug candidate developed from a molecule in the venom of the Fraser Island funnel web spider can prevent damage caused by a heart attack and extend donor heart life for organ transplants. The treatment blocks a death signal sent from the heart after an attack, reducing cell death and improving survival.

SourceUniversity of Queensland·JournalCirculation·DateJul 16, 2021

Scientists find liver drug candidates among pesticides

Researchers from Skoltech and their colleagues discovered promising compounds among pest control chemicals that inhibit the synthesis of hyaluronic acid, a key component in connective tissue. These compounds show potential as anti-fibrotic drugs for treating liver fibrosis.

SourceSkolkovo Institute of Science and Technology (Skoltech)·JournalGlycobiology·DateJul 8, 2021
Sony Alpha a7 IV (Body Only)

Sony Alpha a7 IV (Body Only) delivers reliable low-light performance and rugged build for astrophotography, lab documentation, and field expeditions.

Study identifies existing drugs that could be repurposed to treat gonorrhea

A study at ECCMID identifies existing drugs that could be repurposed to treat gonorrhoea by targeting efflux pumps, which remove toxic compounds from bacterial cells. The research found 57 potential drug candidates, including dequalinium and doxorubicin, which may serve as lead compounds for new gonorrhea treatments.

SourceEuropean Society of Clinical Microbiology and Infectious Diseases·DateJun 30, 2021

Alzheimer's and aducanumab: Unjust profits and false hopes

The FDA's approval of aducanumab for Alzheimer's disease treatment has sparked ethical issues, with billions of dollars in Medicare resources at risk. Physicians face difficult choices between facilitating unjust access to the drug or denying it to desperate patients and families.

SourceThe Hastings Center·JournalHastings Center Report·DateJun 28, 2021

Super productive 3D bioprinter could help speed up drug development

Researchers at UC San Diego developed a high-throughput 3D bioprinting technology that can produce 96-well arrays of living human tissue samples in just 30 minutes, accelerating preclinical drug screening and disease modeling. This could potentially reduce the time and cost associated with drug development.

SourceUniversity of California - San Diego·JournalBiofabrication·DateJun 8, 2021
CalDigit TS4 Thunderbolt 4 Dock

CalDigit TS4 Thunderbolt 4 Dock simplifies serious desks with 18 ports for high-speed storage, monitors, and instruments across Mac and PC setups.

Researchers discover SARS-CoV-2 inhibitors

A research team has discovered two families of active substances that can block the replication of SARS-CoV-2 by targeting its main protease enzyme. The drug candidates show promise for therapeutic development, but extensive clinical trials are still required.

SourceUniversity of Bonn·JournalAngewandte Chemie International Edition·DateMar 3, 2021
Garmin GPSMAP 67i with inReach

Garmin GPSMAP 67i with inReach provides rugged GNSS navigation, satellite messaging, and SOS for backcountry geology and climate field teams.

Research agreement focuses on battlefield injuries

OYE Therapeutics is developing a new life-saving strategy to reduce mortality and morbidity resulting from battlefield injuries. The company, in partnership with USU and HJF, aims to enhance acute pain control at the point-of-injury through its drug product pipeline.

SourcePurdue University·DateFeb 25, 2021

Screening for macrocyclic peptides

Researchers designed a simple screening assay based on competitive binding to identify peptide candidates with high binding affinity for ubiquitin. The dimers of cyclic peptides were found to be more potent than control peptides and induced cell death in live cancer cell lines.

SourceWiley·JournalAngewandte Chemie International Edition·DateFeb 22, 2021

Neutrons probe molecular behavior of proposed COVID-19 drug candidates

Researchers analyze molecular dynamics of proposed COVID-19 drug candidates to understand their interactions with target proteins in human cells. They found that certain parts of the molecules can move more easily once hydrated, which could influence how efficiently a drug takes on shapes associated with different biological functions.

SourceDOE/Oak Ridge National Laboratory·JournalThe Journal of Physical Chemistry Letters·DateFeb 1, 2021
Fluke 87V Industrial Digital Multimeter

Fluke 87V Industrial Digital Multimeter is a trusted meter for precise measurements during instrument integration, repairs, and field diagnostics.

Remdesivir disrupts COVID-19 virus better than other similar drugs

Researchers at the University of Chicago used computational simulations to understand how remdesivir works against SARS-CoV-2. They found that remdesivir binds strongly to the virus and destabilizes its protein complex, reducing replication. This study provides insights into the molecular mechanism of remdesivir and its potential for e...

SourceUniversity of Chicago·JournalACS Central Science·DateJan 29, 2021

New £1.6 million research project for MND drug candidate

Researchers have secured a £1.6 million grant to develop M102, a potential breakthrough in treating motor neuron disease (MND). The drug's neuroprotective properties were discovered by the University of Sheffield's Institute for Translational Neuroscience (SITraN), which will now advance its translational development.

SourceUniversity of Sheffield·DateJan 26, 2021

Using artificial intelligence to find new uses for existing medications

Scientists developed a machine-learning framework to identify potential repurposed drugs for diseases, using massive amounts of data from patient care records. The analysis suggested six candidates, including metformin and escitalopram, which are currently being tested.

SourceOhio State University·JournalNature Machine Intelligence·DateJan 4, 2021
GQ GMC-500Plus Geiger Counter

GQ GMC-500Plus Geiger Counter logs beta, gamma, and X-ray levels for environmental monitoring, training labs, and safety demonstrations.

Beetroot peptide as potential drug candidate for treating diseases

Researchers at MedUni Vienna's Institute of Pharmacology have isolated a beetroot peptide that inhibits prolyl oligopeptidase, an enzyme involved in the breakdown of protein hormones in the body. The study suggests that this peptide could be a promising drug candidate for treating neurodegenerative and autoimmune diseases.

SourceMedical University of Vienna·JournalJournal of Natural Products·DateOct 30, 2020

Machine learning helps hunt for COVID-19 therapies

Researchers at Michigan State University have developed a deep learning model to predict the binding sites of known protease inhibitors targeting the SARS-CoV-2 main protease. The model can help drug developers prioritize promising candidates and save time and money in the early stages of drug development.

SourceMichigan State University·JournalChemical Science·DateOct 28, 2020
Celestron NexStar 8SE Computerized Telescope

Celestron NexStar 8SE Computerized Telescope combines portable Schmidt-Cassegrain optics with GoTo pointing for outreach nights and field campaigns.

Drug repurposing

University of New Mexico researchers have identified three medications with potential to treat SARS-CoV-2 infection: amodiaquine, zuclophentixol, and nebivolol. These drugs showed promise in test tube experiments and could be combined with remdesivir for a more potent attack.

SourceUniversity of New Mexico Health Sciences Center·JournalACS Pharmacology & Translational Science·DateOct 16, 2020

Repurposed anti-malarial compounds kill diarrheal parasite, study finds

Researchers repurpose anti-malarial compounds to target the intestinal parasite Cryptosporidium, killing it in cell cultures and immunocompromised mice. The compounds work by inhibiting an enzyme responsible for protein production within the parasite.

SourceUniversity of Illinois at Urbana-Champaign, News Bureau·JournalScience Translational Medicine·DateOct 1, 2020

Predicting the future of liver-safe drugs

A polygenic risk score has been developed to predict drug-induced liver injury, using genomic data and organoid models. The score can identify patients at risk of liver damage, allowing for safer medication choice and dosage.

SourceTokyo Medical and Dental University·JournalNature Medicine·DateSep 18, 2020
AmScope B120C-5M Compound Microscope

AmScope B120C-5M Compound Microscope supports teaching labs and QA checks with LED illumination, mechanical stage, and included 5MP camera.

$11.4 million NIH grant advances drug to treat nicotine addiction

A $11.4 million NIH grant has funded the advancement of a novel drug candidate, SBP-9330, targeting a neuronal signaling pathway underlying addictive behaviors to treat nicotine addiction. The drug is expected to be effective in reducing nicotine self-administration and may broaden its indication to other types of addiction.

SourceSanford Burnham Prebys·DateSep 16, 2020

Scientists identify promising new ALS drug candidates

Researchers have developed novel Selenium-based compounds that can stabilize the SOD1 protein, which causes ALS. These compounds show improved in vitro therapeutic effects and demonstrate disease onset delay in an ALS mouse model. The findings hold promise for a new class of drug candidates for ALS treatment.

SourceUniversity of Liverpool·JournalEBioMedicine·DateSep 1, 2020

Machine learning makes drug repurposing for psychiatric disorders more effective

Researchers used machine learning to correlate information on drugs, genes, and diseases, identifying 63 drugs targeting 31 genes as potential candidates for psychiatric and neurological treatment. The approach will also be applied to search for correlations between drugs, genes, and COVID-19.

SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalTranslational Psychiatry·DateAug 3, 2020
Sky-Watcher EQ6-R Pro Equatorial Mount

Sky-Watcher EQ6-R Pro Equatorial Mount provides precise tracking capacity for deep-sky imaging rigs during long astrophotography sessions.

Compounds halt SARS-CoV-2 replication by targeting key viral enzyme

Researchers identify four promising antiviral drug candidates that block SARS-CoV-2 replication by targeting the main protease enzyme. The most effective compound, GC-376, demonstrates potent chemical and structural interactions with the viral protein, making it a potential candidate for repurposing as a COVID-19 treatment.

SourceUniversity of South Florida (USF Health)·JournalCell Research·DateJul 6, 2020

NUS-led team develops artificial intelligence platform to combat infectious diseases

A NUS-led team has developed an artificial intelligence platform called IDentif.AI to rapidly identify optimal drug combination therapies for infectious diseases. The platform uses machine learning to examine billions of possible combinations and doses, resulting in unprecedented speed and accuracy in discovering new treatments.

SourceNational University of Singapore·JournalAdvanced Therapeutics·DateApr 27, 2020